منابع مشابه
Anti-VEGF and Beyond
Department of Ophthalmology, University Medical Center Göttingen, Göttingen, Germany Artemis Eye Clinic, Dillenburg, Germany Internationale Innovative Augenchirurgie, Duesseldorf, Germany International Vision Correction Research Centre Network (IVCRC.net), Department of Ophthalmology, University of Heidelberg and Eyeclinics Ahaus-Raesfeld-Rheine, Dr. Gerl & Colleagues, Ahaus Lag, Germany Depart...
متن کاملBeyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy.
Antiangiogenesis is a promising antitumor strategy that inhibits tumor vascular formation to suppress tumor growth. Specifically, targeting VEGF has shown therapeutic benefits in many cancer types, leading to its approval as the first antiangiogenic drug by the Food and Drug Administration in the United States. It is known, however, that patients will experience unfavorable side effects as the ...
متن کاملBeyond VEGF—The Weisenfeld Lecture
Purpose To review advances made in the treatment of age-related macular degeneration (AMD) and share perspectives on the future of AMD treatment. Methods Review of published clinical and experimental studies. Results Inhibitors of vascular endothelial growth factor (VEGF) truly revolutionized the treatment of AMD. However, available results from longer-term studies suggest that a degenerati...
متن کاملPazopanib and anti-VEGF therapy
Pazopanib (Votrient™, GlaxoSmithKline), a multi-kinase inhibitor with activity against VEGFR and other receptors, was recently approved by the FDA for the treatment of advanced renal cell carcinoma (RCC). Here, we review the history of its development, together with an overview of VEGF and its receptors and co-receptors. Results from selected clinical trial data in RCC and other malignant disea...
متن کاملAflibercept (VEGF Trap-eye): the newest anti-VEGF drug
The introduction of anti-vascular endothelial growth factor (anti-VEGF) drugs to ophthalmology over the past 7 years has revolutionised the treatment of exudative age-related macular degeneration (AMD) and holds great promise for diabetic macular oedema, branch and central retinal vein occlusions, and retinopathy of prematurity. Each of the three available drugs (pegaptanib, bevacizumab and ran...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Eye
سال: 2020
ISSN: 0950-222X,1476-5454
DOI: 10.1038/s41433-020-0888-y